4
Changes in Ownership
Aardvark Therapeutics, Inc. Filed Acc 0001193125-26-455757
Options or other derivatives
- Chief Executive Officer acquired 793,951 shares (grant or award)
- Chief Executive Officer returned 793,951 shares (to the company)
From the SEC's structured data for this filing
Trades in this filing
Lee Tien-Li · Chief Executive Officer
Table II: Derivative
6 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-11-06 | Grant or award : show line 1 in the form Stock Option (right to buy) | +203,851 | 203,851 | D |
| 2026-11-06 | Returned to the company : show line 2 in the form Stock Option (right to buy) | −203,851 | 0 | D |
| 2026-11-06 | Grant or award : show line 3 in the form Stock Option (right to buy) | +549,534 | 549,534 | D |
| 2026-11-06 | Returned to the company : show line 4 in the form Stock Option (right to buy) | −549,534 | 0 | D |
| 2026-11-06 | Grant or award : show line 5 in the form Stock Option (right to buy) | +40,566 | 40,566 | D |
| 2026-11-06 | Returned to the company : show line 6 in the form Stock Option (right to buy) | −40,566 | 0 | D |
Loading xslF345X06/ownership.xml…